IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice
- 474 Downloads
Three landmark genome-wide association studies (GWAS) published in 2009 identified the interleukin (IL) 28B gene locus as pivotal to the pathogenesis of hepatitis C virus (HCV) infection. Polymorphisms near the IL28B gene not only predicted treatment-induced and spontaneous recovery from HCV infection, but they also explained, to some extent, the difference in response rates between Caucasians and African Americans to standard therapy with pegylated interferon and ribavirin. The revelation that IL28B, an innate cytokine, plays an essential role in the pathogenesis, outcomes, and treatment responses to HCV infection has triggered a gold rush and an ever increasing number of reports on the subject are being presented at international conferences and in scientific journals. This review will summarize currently available data on the clinical impact of IL28B polymorphisms on HCV infection and the potential mechanisms for its effects. It will conclude with a discussion on how the research observations may translate into clinical practice and drug development.
KeywordsHCV IL28B Interferon-α GWAS Treatment
Hepatitis C virus
Sustained virological response
Work on this review was in part supported by research grants from the National Health and Medical Research Council of Australia and by an Australian ARC linkage grant. J.G. is supported by the Robert W. Storr bequest to the University of Sydney Medical Foundation.
Conflict of interest statement
The authors have filed a provisional patent application on the genetic variants described in this paper.
- 4.WHO. Hepatitis C. Fact Sheet No. 164. Revised October 2000. http://www.who.int/mediacentre/factsheets/fs164/en/ (2000).
- 8.Australia and New Zealand Liver Transplant Registry ebSVL, G.A. Balderson. ANZLT Registry Report 2008, Brisbane, Queensland, Australia, 2008.Google Scholar
- 9.NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1–46.Google Scholar
- 11.Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338–45, 1345.e1–7.Google Scholar
- 12.Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of SVR in HCV-1 patients. Gastroenterology. 2010;in press.Google Scholar
- 14.Montes-Cano MA, García-Lozano JR, Abad-Molina C, Romero-Gómez M, Barroso N, Aguilar-Reina J, et al. IL28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology. 2010;52:33–7.Google Scholar
- 15.Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Amino acid substitution in HCV core region and genetic variation near IL28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;in press.Google Scholar
- 18.Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically hepatitis C virus infected patients. J Hepatol. 2010;52:S449.Google Scholar
- 28.Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 2009;10:702–14.CrossRefPubMedGoogle Scholar
- 30.Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem. 2004;279:32269–74.CrossRefPubMedGoogle Scholar
- 36.Honda M, Sakai A, Yamashita T, Nakamoto E, Sakai Y, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in IL28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010;in press.Google Scholar
- 37.Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, et al. Common variation of IL28 affects intrahepatic expression of interferon stimulated genesis and correlates with effect of peg-interferon and ribavirin combination therapy. J Hepatol. 2010;52:S449.Google Scholar